nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—PTGS2—thyroid cancer	0.407	1	CbGaD
Mefenamic acid—AKR1C3—Doxorubicin—thyroid cancer	0.294	0.819	CbGbCtD
Mefenamic acid—CYP2C8—Sorafenib—thyroid cancer	0.0383	0.107	CbGbCtD
Mefenamic acid—CYP2C9—Sorafenib—thyroid cancer	0.0267	0.0744	CbGbCtD
Mefenamic acid—Acetylsalicylic acid—TP53—thyroid cancer	0.00138	0.233	CrCbGaD
Mefenamic acid—Floctafenine—PTGS2—thyroid cancer	0.000709	0.12	CrCbGaD
Mefenamic acid—Lumiracoxib—PTGS2—thyroid cancer	0.000457	0.0772	CrCbGaD
Mefenamic acid—Tiaprofenic acid—PTGS2—thyroid cancer	0.000457	0.0772	CrCbGaD
Mefenamic acid—AKR1C2—Metabolism—NDUFA13—thyroid cancer	0.000438	0.00461	CbGpPWpGaD
Mefenamic acid—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000436	0.00459	CbGpPWpGaD
Mefenamic acid—Nepafenac—PTGS2—thyroid cancer	0.000435	0.0734	CrCbGaD
Mefenamic acid—Angioedema—Sorafenib—thyroid cancer	0.000429	0.00323	CcSEcCtD
Mefenamic acid—Syncope—Sorafenib—thyroid cancer	0.000421	0.00317	CcSEcCtD
Mefenamic acid—Leukopenia—Sorafenib—thyroid cancer	0.00042	0.00316	CcSEcCtD
Mefenamic acid—Ulcer—Epirubicin—thyroid cancer	0.00042	0.00316	CcSEcCtD
Mefenamic acid—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.000418	0.00315	CcSEcCtD
Mefenamic acid—Loss of consciousness—Sorafenib—thyroid cancer	0.000413	0.00311	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—CHST14—thyroid cancer	0.000412	0.00433	CbGpPWpGaD
Mefenamic acid—Asthenia—Vandetanib—thyroid cancer	0.000408	0.00307	CcSEcCtD
Mefenamic acid—Niflumic Acid—PTGS2—thyroid cancer	0.000407	0.0688	CrCbGaD
Mefenamic acid—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.000407	0.00306	CcSEcCtD
Mefenamic acid—Hypertension—Sorafenib—thyroid cancer	0.000406	0.00305	CcSEcCtD
Mefenamic acid—Pruritus—Vandetanib—thyroid cancer	0.000402	0.00303	CcSEcCtD
Mefenamic acid—Oliguria—Doxorubicin—thyroid cancer	0.000399	0.003	CcSEcCtD
Mefenamic acid—Glossitis—Doxorubicin—thyroid cancer	0.000399	0.003	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000397	0.00299	CcSEcCtD
Mefenamic acid—Dry mouth—Sorafenib—thyroid cancer	0.000391	0.00294	CcSEcCtD
Mefenamic acid—Eructation—Epirubicin—thyroid cancer	0.00039	0.00294	CcSEcCtD
Mefenamic acid—Diarrhoea—Vandetanib—thyroid cancer	0.000389	0.00293	CcSEcCtD
Mefenamic acid—Ulcer—Doxorubicin—thyroid cancer	0.000388	0.00292	CcSEcCtD
Mefenamic acid—Cystitis noninfective—Epirubicin—thyroid cancer	0.000388	0.00292	CcSEcCtD
Mefenamic acid—Melaena—Epirubicin—thyroid cancer	0.000388	0.00292	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—TRIM24—thyroid cancer	0.000384	0.00404	CbGpPWpGaD
Mefenamic acid—Cystitis—Epirubicin—thyroid cancer	0.000383	0.00289	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Sorafenib—thyroid cancer	0.000383	0.00289	CcSEcCtD
Mefenamic acid—Colitis—Epirubicin—thyroid cancer	0.000381	0.00287	CcSEcCtD
Mefenamic acid—Infection—Sorafenib—thyroid cancer	0.000381	0.00287	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—MINPP1—thyroid cancer	0.000378	0.00398	CbGpPWpGaD
Mefenamic acid—Shock—Sorafenib—thyroid cancer	0.000377	0.00284	CcSEcCtD
Mefenamic acid—Fluid retention—Epirubicin—thyroid cancer	0.000377	0.00284	CcSEcCtD
Mefenamic acid—Dizziness—Vandetanib—thyroid cancer	0.000376	0.00283	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Sorafenib—thyroid cancer	0.000375	0.00283	CcSEcCtD
Mefenamic acid—Aplastic anaemia—Epirubicin—thyroid cancer	0.000373	0.00281	CcSEcCtD
Mefenamic acid—Skin disorder—Sorafenib—thyroid cancer	0.000372	0.0028	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000368	0.00387	CbGpPWpGaD
Mefenamic acid—Anorexia—Sorafenib—thyroid cancer	0.000365	0.00275	CcSEcCtD
Mefenamic acid—Oesophagitis—Epirubicin—thyroid cancer	0.000363	0.00273	CcSEcCtD
Mefenamic acid—Coma—Epirubicin—thyroid cancer	0.000363	0.00273	CcSEcCtD
Mefenamic acid—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000362	0.00381	CbGpPWpGaD
Mefenamic acid—Vomiting—Vandetanib—thyroid cancer	0.000361	0.00272	CcSEcCtD
Mefenamic acid—Salsalate—PTGS2—thyroid cancer	0.000361	0.061	CrCbGaD
Mefenamic acid—AKR1C1—Disease—CHST14—thyroid cancer	0.000361	0.0038	CbGpPWpGaD
Mefenamic acid—Eructation—Doxorubicin—thyroid cancer	0.000361	0.00272	CcSEcCtD
Mefenamic acid—Bladder pain—Epirubicin—thyroid cancer	0.000359	0.0027	CcSEcCtD
Mefenamic acid—Ecchymosis—Epirubicin—thyroid cancer	0.000359	0.0027	CcSEcCtD
Mefenamic acid—Cystitis noninfective—Doxorubicin—thyroid cancer	0.000359	0.0027	CcSEcCtD
Mefenamic acid—Melaena—Doxorubicin—thyroid cancer	0.000359	0.0027	CcSEcCtD
Mefenamic acid—Rash—Vandetanib—thyroid cancer	0.000358	0.0027	CcSEcCtD
Mefenamic acid—Dermatitis—Vandetanib—thyroid cancer	0.000358	0.00269	CcSEcCtD
Mefenamic acid—Headache—Vandetanib—thyroid cancer	0.000356	0.00268	CcSEcCtD
Mefenamic acid—Meclofenamic acid—PTGS2—thyroid cancer	0.000356	0.0601	CrCbGaD
Mefenamic acid—Cystitis—Doxorubicin—thyroid cancer	0.000355	0.00267	CcSEcCtD
Mefenamic acid—Colitis—Doxorubicin—thyroid cancer	0.000353	0.00266	CcSEcCtD
Mefenamic acid—Fluid retention—Doxorubicin—thyroid cancer	0.000349	0.00263	CcSEcCtD
Mefenamic acid—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000345	0.0026	CcSEcCtD
Mefenamic acid—Sepsis—Epirubicin—thyroid cancer	0.000345	0.00259	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—TRIM33—thyroid cancer	0.000342	0.0036	CbGpPWpGaD
Mefenamic acid—Dyspnoea—Sorafenib—thyroid cancer	0.000342	0.00257	CcSEcCtD
Mefenamic acid—Lymphadenopathy—Epirubicin—thyroid cancer	0.000338	0.00254	CcSEcCtD
Mefenamic acid—Nausea—Vandetanib—thyroid cancer	0.000338	0.00254	CcSEcCtD
Mefenamic acid—Dyspepsia—Sorafenib—thyroid cancer	0.000337	0.00254	CcSEcCtD
Mefenamic acid—Coma—Doxorubicin—thyroid cancer	0.000336	0.00253	CcSEcCtD
Mefenamic acid—Oesophagitis—Doxorubicin—thyroid cancer	0.000336	0.00253	CcSEcCtD
Mefenamic acid—Decreased appetite—Sorafenib—thyroid cancer	0.000333	0.00251	CcSEcCtD
Mefenamic acid—Bladder pain—Doxorubicin—thyroid cancer	0.000332	0.0025	CcSEcCtD
Mefenamic acid—Ecchymosis—Doxorubicin—thyroid cancer	0.000332	0.0025	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—HPGD—thyroid cancer	0.000332	0.00349	CbGpPWpGaD
Mefenamic acid—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000331	0.00249	CcSEcCtD
Mefenamic acid—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.00033	0.00347	CbGpPWpGaD
Mefenamic acid—Photosensitivity—Epirubicin—thyroid cancer	0.000328	0.00247	CcSEcCtD
Mefenamic acid—Constipation—Sorafenib—thyroid cancer	0.000328	0.00247	CcSEcCtD
Mefenamic acid—Vascular purpura—Epirubicin—thyroid cancer	0.000322	0.00243	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—NDUFA13—thyroid cancer	0.000322	0.00338	CbGpPWpGaD
Mefenamic acid—Hepatic failure—Epirubicin—thyroid cancer	0.000321	0.00241	CcSEcCtD
Mefenamic acid—Sepsis—Doxorubicin—thyroid cancer	0.000319	0.0024	CcSEcCtD
Mefenamic acid—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000318	0.00239	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000313	0.00236	CcSEcCtD
Mefenamic acid—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000313	0.00235	CcSEcCtD
Mefenamic acid—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000305	0.0023	CcSEcCtD
Mefenamic acid—Urticaria—Sorafenib—thyroid cancer	0.000305	0.00229	CcSEcCtD
Mefenamic acid—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000304	0.0032	CbGpPWpGaD
Mefenamic acid—Photosensitivity—Doxorubicin—thyroid cancer	0.000304	0.00229	CcSEcCtD
Mefenamic acid—Abdominal pain—Sorafenib—thyroid cancer	0.000303	0.00228	CcSEcCtD
Mefenamic acid—Body temperature increased—Sorafenib—thyroid cancer	0.000303	0.00228	CcSEcCtD
Mefenamic acid—Renal impairment—Epirubicin—thyroid cancer	0.000303	0.00228	CcSEcCtD
Mefenamic acid—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000303	0.00319	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—CHST14—thyroid cancer	0.000302	0.00318	CbGpPWpGaD
Mefenamic acid—Purpura—Epirubicin—thyroid cancer	0.000299	0.00225	CcSEcCtD
Mefenamic acid—Fenoprofen—PTGS2—thyroid cancer	0.000298	0.0504	CrCbGaD
Mefenamic acid—Vascular purpura—Doxorubicin—thyroid cancer	0.000298	0.00224	CcSEcCtD
Mefenamic acid—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000298	0.00224	CcSEcCtD
Mefenamic acid—Hepatic failure—Doxorubicin—thyroid cancer	0.000297	0.00223	CcSEcCtD
Mefenamic acid—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000294	0.00221	CcSEcCtD
Mefenamic acid—Hyponatraemia—Epirubicin—thyroid cancer	0.000289	0.00218	CcSEcCtD
Mefenamic acid—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000288	0.00217	CcSEcCtD
Mefenamic acid—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000284	0.00299	CbGpPWpGaD
Mefenamic acid—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000283	0.00213	CcSEcCtD
Mefenamic acid—Renal impairment—Doxorubicin—thyroid cancer	0.00028	0.00211	CcSEcCtD
Mefenamic acid—Purpura—Doxorubicin—thyroid cancer	0.000277	0.00208	CcSEcCtD
Mefenamic acid—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000276	0.00207	CcSEcCtD
Mefenamic acid—Asthenia—Sorafenib—thyroid cancer	0.000275	0.00207	CcSEcCtD
Mefenamic acid—Pruritus—Sorafenib—thyroid cancer	0.000271	0.00204	CcSEcCtD
Mefenamic acid—Acetylsalicylic acid—PTGS2—thyroid cancer	0.00027	0.0456	CrCbGaD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000269	0.00283	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000268	0.00282	CbGpPWpGaD
Mefenamic acid—Hyponatraemia—Doxorubicin—thyroid cancer	0.000268	0.00202	CcSEcCtD
Mefenamic acid—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000267	0.00201	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Epirubicin—thyroid cancer	0.000266	0.002	CcSEcCtD
Mefenamic acid—Diarrhoea—Sorafenib—thyroid cancer	0.000262	0.00197	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00026	0.00195	CcSEcCtD
Mefenamic acid—AKR1C3—Disease—TRIM24—thyroid cancer	0.000258	0.00272	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000255	0.00268	CbGpPWpGaD
Mefenamic acid—Gastritis—Epirubicin—thyroid cancer	0.000255	0.00192	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—MINPP1—thyroid cancer	0.000254	0.00268	CbGpPWpGaD
Mefenamic acid—Dizziness—Sorafenib—thyroid cancer	0.000254	0.00191	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—CALCB—thyroid cancer	0.000253	0.00266	CbGpPWpGaD
Mefenamic acid—Asthma—Epirubicin—thyroid cancer	0.000249	0.00188	CcSEcCtD
Mefenamic acid—Eosinophilia—Epirubicin—thyroid cancer	0.000247	0.00186	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000246	0.00185	CcSEcCtD
Mefenamic acid—Pancreatitis—Epirubicin—thyroid cancer	0.000244	0.00184	CcSEcCtD
Mefenamic acid—Vomiting—Sorafenib—thyroid cancer	0.000244	0.00183	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—HPGD—thyroid cancer	0.000244	0.00256	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CHST14—thyroid cancer	0.000243	0.00256	CbGpPWpGaD
Mefenamic acid—Rash—Sorafenib—thyroid cancer	0.000242	0.00182	CcSEcCtD
Mefenamic acid—Dermatitis—Sorafenib—thyroid cancer	0.000241	0.00182	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00024	0.00181	CcSEcCtD
Mefenamic acid—Headache—Sorafenib—thyroid cancer	0.00024	0.00181	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—TRIM33—thyroid cancer	0.00024	0.00252	CbGpPWpGaD
Mefenamic acid—Pancytopenia—Epirubicin—thyroid cancer	0.000237	0.00178	CcSEcCtD
Mefenamic acid—Gastritis—Doxorubicin—thyroid cancer	0.000236	0.00178	CcSEcCtD
Mefenamic acid—Dysuria—Epirubicin—thyroid cancer	0.000233	0.00175	CcSEcCtD
Mefenamic acid—Asthma—Doxorubicin—thyroid cancer	0.000231	0.00174	CcSEcCtD
Mefenamic acid—AKR1C3—Disease—TRIM33—thyroid cancer	0.00023	0.00242	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—TCF7L1—thyroid cancer	0.000228	0.0024	CbGpPWpGaD
Mefenamic acid—Eosinophilia—Doxorubicin—thyroid cancer	0.000228	0.00172	CcSEcCtD
Mefenamic acid—Nausea—Sorafenib—thyroid cancer	0.000228	0.00171	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000227	0.00171	CcSEcCtD
Mefenamic acid—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000226	0.00238	CbGpPWpGaD
Mefenamic acid—Pancreatitis—Doxorubicin—thyroid cancer	0.000226	0.0017	CcSEcCtD
Mefenamic acid—Hyperglycaemia—Epirubicin—thyroid cancer	0.000225	0.00169	CcSEcCtD
Mefenamic acid—Pneumonia—Epirubicin—thyroid cancer	0.000223	0.00168	CcSEcCtD
Mefenamic acid—Salicylic acid—PTGS2—thyroid cancer	0.000222	0.0375	CrCbGaD
Mefenamic acid—Drowsiness—Epirubicin—thyroid cancer	0.000222	0.00167	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00022	0.00166	CcSEcCtD
Mefenamic acid—Pancytopenia—Doxorubicin—thyroid cancer	0.000219	0.00165	CcSEcCtD
Mefenamic acid—Renal failure—Epirubicin—thyroid cancer	0.000218	0.00164	CcSEcCtD
Mefenamic acid—Stomatitis—Epirubicin—thyroid cancer	0.000217	0.00163	CcSEcCtD
Mefenamic acid—Jaundice—Epirubicin—thyroid cancer	0.000217	0.00163	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—NDUFA13—thyroid cancer	0.000216	0.00228	CbGpPWpGaD
Mefenamic acid—Conjunctivitis—Epirubicin—thyroid cancer	0.000216	0.00163	CcSEcCtD
Mefenamic acid—Dysuria—Doxorubicin—thyroid cancer	0.000216	0.00162	CcSEcCtD
Mefenamic acid—Haematuria—Epirubicin—thyroid cancer	0.000212	0.00159	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00021	0.00158	CcSEcCtD
Mefenamic acid—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000208	0.00157	CcSEcCtD
Mefenamic acid—Agranulocytosis—Epirubicin—thyroid cancer	0.000207	0.00156	CcSEcCtD
Mefenamic acid—Pneumonia—Doxorubicin—thyroid cancer	0.000207	0.00156	CcSEcCtD
Mefenamic acid—Drowsiness—Doxorubicin—thyroid cancer	0.000206	0.00155	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000204	0.00153	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—CHST14—thyroid cancer	0.000203	0.00214	CbGpPWpGaD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000203	0.00214	CbGpPWpGaD
Mefenamic acid—Renal failure—Doxorubicin—thyroid cancer	0.000202	0.00152	CcSEcCtD
Mefenamic acid—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000201	0.00212	CbGpPWpGaD
Mefenamic acid—Haemoglobin—Epirubicin—thyroid cancer	0.0002	0.00151	CcSEcCtD
Mefenamic acid—Jaundice—Doxorubicin—thyroid cancer	0.0002	0.00151	CcSEcCtD
Mefenamic acid—Stomatitis—Doxorubicin—thyroid cancer	0.0002	0.00151	CcSEcCtD
Mefenamic acid—Conjunctivitis—Doxorubicin—thyroid cancer	0.0002	0.0015	CcSEcCtD
Mefenamic acid—Hepatitis—Epirubicin—thyroid cancer	0.000199	0.0015	CcSEcCtD
Mefenamic acid—Haemorrhage—Epirubicin—thyroid cancer	0.000199	0.0015	CcSEcCtD
Mefenamic acid—Diclofenac—PTGS2—thyroid cancer	0.000199	0.0336	CrCbGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000198	0.00208	CbGpPWpGaD
Mefenamic acid—Urinary tract disorder—Epirubicin—thyroid cancer	0.000197	0.00148	CcSEcCtD
Mefenamic acid—Haematuria—Doxorubicin—thyroid cancer	0.000196	0.00148	CcSEcCtD
Mefenamic acid—Urethral disorder—Epirubicin—thyroid cancer	0.000195	0.00147	CcSEcCtD
Mefenamic acid—Flurbiprofen—PTGS2—thyroid cancer	0.000195	0.0329	CrCbGaD
Mefenamic acid—Agranulocytosis—Doxorubicin—thyroid cancer	0.000192	0.00144	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—TPR—thyroid cancer	0.000191	0.00201	CbGpPWpGaD
Mefenamic acid—Erythema multiforme—Epirubicin—thyroid cancer	0.000189	0.00142	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—PRKAR1A—thyroid cancer	0.000188	0.00197	CbGpPWpGaD
Mefenamic acid—Tinnitus—Epirubicin—thyroid cancer	0.000186	0.0014	CcSEcCtD
Mefenamic acid—Haemoglobin—Doxorubicin—thyroid cancer	0.000185	0.0014	CcSEcCtD
Mefenamic acid—Hepatitis—Doxorubicin—thyroid cancer	0.000185	0.00139	CcSEcCtD
Mefenamic acid—Haemorrhage—Doxorubicin—thyroid cancer	0.000185	0.00139	CcSEcCtD
Mefenamic acid—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000184	0.00194	CbGpPWpGaD
Mefenamic acid—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000183	0.00193	CbGpPWpGaD
Mefenamic acid—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000183	0.00193	CbGpPWpGaD
Mefenamic acid—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000182	0.00137	CcSEcCtD
Mefenamic acid—Urethral disorder—Doxorubicin—thyroid cancer	0.000181	0.00136	CcSEcCtD
Mefenamic acid—Arrhythmia—Epirubicin—thyroid cancer	0.000178	0.00134	CcSEcCtD
Mefenamic acid—Alopecia—Epirubicin—thyroid cancer	0.000176	0.00133	CcSEcCtD
Mefenamic acid—Ketoprofen—PTGS2—thyroid cancer	0.000176	0.0298	CrCbGaD
Mefenamic acid—Mental disorder—Epirubicin—thyroid cancer	0.000175	0.00132	CcSEcCtD
Mefenamic acid—Erythema multiforme—Doxorubicin—thyroid cancer	0.000174	0.00131	CcSEcCtD
Mefenamic acid—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000174	0.00183	CbGpPWpGaD
Mefenamic acid—Tinnitus—Doxorubicin—thyroid cancer	0.000172	0.00129	CcSEcCtD
Mefenamic acid—Flatulence—Epirubicin—thyroid cancer	0.000171	0.00129	CcSEcCtD
Mefenamic acid—Tension—Epirubicin—thyroid cancer	0.00017	0.00128	CcSEcCtD
Mefenamic acid—AKR1C3—Signaling Pathways—CALCB—thyroid cancer	0.00017	0.00179	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.00017	0.00179	CbGpPWpGaD
Mefenamic acid—Nervousness—Epirubicin—thyroid cancer	0.000169	0.00127	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—TPR—thyroid cancer	0.000167	0.00176	CbGpPWpGaD
Mefenamic acid—Arrhythmia—Doxorubicin—thyroid cancer	0.000165	0.00124	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—PRKAR1A—thyroid cancer	0.000164	0.00173	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—HPGD—thyroid cancer	0.000164	0.00173	CbGpPWpGaD
Mefenamic acid—Vision blurred—Epirubicin—thyroid cancer	0.000164	0.00123	CcSEcCtD
Mefenamic acid—Alopecia—Doxorubicin—thyroid cancer	0.000163	0.00123	CcSEcCtD
Mefenamic acid—Mental disorder—Doxorubicin—thyroid cancer	0.000162	0.00122	CcSEcCtD
Mefenamic acid—AKR1C3—Signaling Pathways—TRIM33—thyroid cancer	0.000161	0.0017	CbGpPWpGaD
Mefenamic acid—Ill-defined disorder—Epirubicin—thyroid cancer	0.000161	0.00121	CcSEcCtD
Mefenamic acid—Anaemia—Epirubicin—thyroid cancer	0.00016	0.00121	CcSEcCtD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00016	0.00169	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TCF7L1—thyroid cancer	0.00016	0.00168	CbGpPWpGaD
Mefenamic acid—Flatulence—Doxorubicin—thyroid cancer	0.000158	0.00119	CcSEcCtD
Mefenamic acid—Tension—Doxorubicin—thyroid cancer	0.000158	0.00119	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—MEN1—thyroid cancer	0.000157	0.00165	CbGpPWpGaD
Mefenamic acid—Malaise—Epirubicin—thyroid cancer	0.000157	0.00118	CcSEcCtD
Mefenamic acid—Nervousness—Doxorubicin—thyroid cancer	0.000156	0.00117	CcSEcCtD
Mefenamic acid—Vertigo—Epirubicin—thyroid cancer	0.000156	0.00117	CcSEcCtD
Mefenamic acid—Syncope—Epirubicin—thyroid cancer	0.000156	0.00117	CcSEcCtD
Mefenamic acid—Leukopenia—Epirubicin—thyroid cancer	0.000155	0.00117	CcSEcCtD
Mefenamic acid—AKR1C3—Disease—TCF7L1—thyroid cancer	0.000154	0.00162	CbGpPWpGaD
Mefenamic acid—Palpitations—Epirubicin—thyroid cancer	0.000153	0.00115	CcSEcCtD
Mefenamic acid—Loss of consciousness—Epirubicin—thyroid cancer	0.000153	0.00115	CcSEcCtD
Mefenamic acid—Vision blurred—Doxorubicin—thyroid cancer	0.000151	0.00114	CcSEcCtD
Mefenamic acid—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000151	0.00159	CbGpPWpGaD
Mefenamic acid—Convulsion—Epirubicin—thyroid cancer	0.00015	0.00113	CcSEcCtD
Mefenamic acid—Hypertension—Epirubicin—thyroid cancer	0.00015	0.00113	CcSEcCtD
Mefenamic acid—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000149	0.00157	CbGpPWpGaD
Mefenamic acid—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000149	0.00112	CcSEcCtD
Mefenamic acid—Anaemia—Doxorubicin—thyroid cancer	0.000148	0.00112	CcSEcCtD
Mefenamic acid—Anxiety—Epirubicin—thyroid cancer	0.000147	0.00111	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000147	0.0011	CcSEcCtD
Mefenamic acid—Discomfort—Epirubicin—thyroid cancer	0.000146	0.0011	CcSEcCtD
Mefenamic acid—Malaise—Doxorubicin—thyroid cancer	0.000145	0.00109	CcSEcCtD
Mefenamic acid—Dry mouth—Epirubicin—thyroid cancer	0.000145	0.00109	CcSEcCtD
Mefenamic acid—Vertigo—Doxorubicin—thyroid cancer	0.000144	0.00109	CcSEcCtD
Mefenamic acid—Syncope—Doxorubicin—thyroid cancer	0.000144	0.00108	CcSEcCtD
Mefenamic acid—Leukopenia—Doxorubicin—thyroid cancer	0.000144	0.00108	CcSEcCtD
Mefenamic acid—Confusional state—Epirubicin—thyroid cancer	0.000143	0.00108	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—SLC5A5—thyroid cancer	0.000143	0.0015	CbGpPWpGaD
Mefenamic acid—Palpitations—Doxorubicin—thyroid cancer	0.000142	0.00107	CcSEcCtD
Mefenamic acid—Oedema—Epirubicin—thyroid cancer	0.000142	0.00107	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Epirubicin—thyroid cancer	0.000142	0.00107	CcSEcCtD
Mefenamic acid—Loss of consciousness—Doxorubicin—thyroid cancer	0.000141	0.00106	CcSEcCtD
Mefenamic acid—Infection—Epirubicin—thyroid cancer	0.000141	0.00106	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—TPR—thyroid cancer	0.00014	0.00147	CbGpPWpGaD
Mefenamic acid—Shock—Epirubicin—thyroid cancer	0.000139	0.00105	CcSEcCtD
Mefenamic acid—Convulsion—Doxorubicin—thyroid cancer	0.000139	0.00105	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Epirubicin—thyroid cancer	0.000139	0.00104	CcSEcCtD
Mefenamic acid—Hypertension—Doxorubicin—thyroid cancer	0.000139	0.00104	CcSEcCtD
Mefenamic acid—Tachycardia—Epirubicin—thyroid cancer	0.000138	0.00104	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—PRKAR1A—thyroid cancer	0.000138	0.00145	CbGpPWpGaD
Mefenamic acid—Skin disorder—Epirubicin—thyroid cancer	0.000138	0.00104	CcSEcCtD
Mefenamic acid—Anxiety—Doxorubicin—thyroid cancer	0.000136	0.00103	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000136	0.00102	CcSEcCtD
Mefenamic acid—Discomfort—Doxorubicin—thyroid cancer	0.000135	0.00102	CcSEcCtD
Mefenamic acid—Anorexia—Epirubicin—thyroid cancer	0.000135	0.00102	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000134	0.00141	CbGpPWpGaD
Mefenamic acid—Dry mouth—Doxorubicin—thyroid cancer	0.000134	0.00101	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000133	0.0014	CbGpPWpGaD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000133	0.0014	CbGpPWpGaD
Mefenamic acid—Hypotension—Epirubicin—thyroid cancer	0.000132	0.000996	CcSEcCtD
Mefenamic acid—Confusional state—Doxorubicin—thyroid cancer	0.000132	0.000995	CcSEcCtD
Mefenamic acid—Oedema—Doxorubicin—thyroid cancer	0.000131	0.000987	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000131	0.000987	CcSEcCtD
Mefenamic acid—Infection—Doxorubicin—thyroid cancer	0.00013	0.00098	CcSEcCtD
Mefenamic acid—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00013	0.00137	CbGpPWpGaD
Mefenamic acid—Shock—Doxorubicin—thyroid cancer	0.000129	0.000971	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000128	0.000966	CcSEcCtD
Mefenamic acid—Insomnia—Epirubicin—thyroid cancer	0.000128	0.000965	CcSEcCtD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000128	0.00135	CbGpPWpGaD
Mefenamic acid—Tachycardia—Doxorubicin—thyroid cancer	0.000128	0.000963	CcSEcCtD
Mefenamic acid—Skin disorder—Doxorubicin—thyroid cancer	0.000127	0.000958	CcSEcCtD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000127	0.00134	CbGpPWpGaD
Mefenamic acid—Paraesthesia—Epirubicin—thyroid cancer	0.000127	0.000958	CcSEcCtD
Mefenamic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000126	0.00133	CbGpPWpGaD
Mefenamic acid—Dyspnoea—Epirubicin—thyroid cancer	0.000126	0.000951	CcSEcCtD
Mefenamic acid—Somnolence—Epirubicin—thyroid cancer	0.000126	0.000948	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—CALCA—thyroid cancer	0.000125	0.00132	CbGpPWpGaD
Mefenamic acid—Anorexia—Doxorubicin—thyroid cancer	0.000125	0.000941	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000125	0.00131	CbGpPWpGaD
Mefenamic acid—Dyspepsia—Epirubicin—thyroid cancer	0.000125	0.000939	CcSEcCtD
Mefenamic acid—Decreased appetite—Epirubicin—thyroid cancer	0.000123	0.000927	CcSEcCtD
Mefenamic acid—Hypotension—Doxorubicin—thyroid cancer	0.000122	0.000922	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000122	0.000921	CcSEcCtD
Mefenamic acid—Constipation—Epirubicin—thyroid cancer	0.000121	0.000912	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—RXRA—thyroid cancer	0.00012	0.00126	CbGpPWpGaD
Mefenamic acid—Insomnia—Doxorubicin—thyroid cancer	0.000119	0.000892	CcSEcCtD
Mefenamic acid—Paraesthesia—Doxorubicin—thyroid cancer	0.000118	0.000886	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—TSHR—thyroid cancer	0.000117	0.00123	CbGpPWpGaD
Mefenamic acid—Dyspnoea—Doxorubicin—thyroid cancer	0.000117	0.00088	CcSEcCtD
Mefenamic acid—Feeling abnormal—Epirubicin—thyroid cancer	0.000117	0.000879	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000117	0.00123	CbGpPWpGaD
Mefenamic acid—Somnolence—Doxorubicin—thyroid cancer	0.000117	0.000877	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000116	0.000872	CcSEcCtD
Mefenamic acid—Dyspepsia—Doxorubicin—thyroid cancer	0.000115	0.000869	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000115	0.00121	CbGpPWpGaD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000114	0.0012	CbGpPWpGaD
Mefenamic acid—Decreased appetite—Doxorubicin—thyroid cancer	0.000114	0.000858	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—CDK1—thyroid cancer	0.000113	0.00119	CbGpPWpGaD
Mefenamic acid—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000113	0.000852	CcSEcCtD
Mefenamic acid—Urticaria—Epirubicin—thyroid cancer	0.000113	0.000847	CcSEcCtD
Mefenamic acid—AKR1C3—Disease—TPR—thyroid cancer	0.000112	0.00118	CbGpPWpGaD
Mefenamic acid—Constipation—Doxorubicin—thyroid cancer	0.000112	0.000844	CcSEcCtD
Mefenamic acid—Body temperature increased—Epirubicin—thyroid cancer	0.000112	0.000843	CcSEcCtD
Mefenamic acid—Abdominal pain—Epirubicin—thyroid cancer	0.000112	0.000843	CcSEcCtD
Mefenamic acid—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000111	0.00117	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PRKAR1A—thyroid cancer	0.000111	0.00116	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00011	0.00116	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MEN1—thyroid cancer	0.00011	0.00116	CbGpPWpGaD
Mefenamic acid—Feeling abnormal—Doxorubicin—thyroid cancer	0.000108	0.000813	CcSEcCtD
Mefenamic acid—AKR1C3—Signaling Pathways—TCF7L1—thyroid cancer	0.000108	0.00113	CbGpPWpGaD
Mefenamic acid—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000107	0.000807	CcSEcCtD
Mefenamic acid—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000106	0.00111	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MEN1—thyroid cancer	0.000106	0.00111	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—SLC5A5—thyroid cancer	0.000105	0.0011	CbGpPWpGaD
Mefenamic acid—Urticaria—Doxorubicin—thyroid cancer	0.000104	0.000784	CcSEcCtD
Mefenamic acid—Abdominal pain—Doxorubicin—thyroid cancer	0.000104	0.00078	CcSEcCtD
Mefenamic acid—Body temperature increased—Doxorubicin—thyroid cancer	0.000104	0.00078	CcSEcCtD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000104	0.00109	CbGpPWpGaD
Mefenamic acid—Asthenia—Epirubicin—thyroid cancer	0.000102	0.000765	CcSEcCtD
Mefenamic acid—Pruritus—Epirubicin—thyroid cancer	0.0001	0.000754	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—PTCH1—thyroid cancer	9.95e-05	0.00105	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.82e-05	0.00103	CbGpPWpGaD
Mefenamic acid—CYP2C8—Biological oxidations—RXRA—thyroid cancer	9.74e-05	0.00102	CbGpPWpGaD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	9.72e-05	0.00102	CbGpPWpGaD
Mefenamic acid—Diarrhoea—Epirubicin—thyroid cancer	9.69e-05	0.00073	CcSEcCtD
Mefenamic acid—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	9.53e-05	0.001	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—TPR—thyroid cancer	9.42e-05	0.000991	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NDUFA13—thyroid cancer	9.42e-05	0.000991	CbGpPWpGaD
Mefenamic acid—Asthenia—Doxorubicin—thyroid cancer	9.41e-05	0.000708	CcSEcCtD
Mefenamic acid—Dizziness—Epirubicin—thyroid cancer	9.37e-05	0.000705	CcSEcCtD
Mefenamic acid—Pruritus—Doxorubicin—thyroid cancer	9.27e-05	0.000698	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—PRKAR1A—thyroid cancer	9.27e-05	0.000975	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—SST—thyroid cancer	9.1e-05	0.000958	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—NRG1—thyroid cancer	9.09e-05	0.000956	CbGpPWpGaD
Mefenamic acid—Vomiting—Epirubicin—thyroid cancer	9.01e-05	0.000678	CcSEcCtD
Mefenamic acid—Diarrhoea—Doxorubicin—thyroid cancer	8.97e-05	0.000675	CcSEcCtD
Mefenamic acid—Rash—Epirubicin—thyroid cancer	8.93e-05	0.000672	CcSEcCtD
Mefenamic acid—PTGS2—Disease—TRIM24—thyroid cancer	8.93e-05	0.000939	CbGpPWpGaD
Mefenamic acid—Dermatitis—Epirubicin—thyroid cancer	8.92e-05	0.000672	CcSEcCtD
Mefenamic acid—Headache—Epirubicin—thyroid cancer	8.88e-05	0.000668	CcSEcCtD
Mefenamic acid—PTGS1—Metabolism—CHST14—thyroid cancer	8.86e-05	0.000932	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—RXRA—thyroid cancer	8.8e-05	0.000926	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—MINPP1—thyroid cancer	8.79e-05	0.000925	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CALCA—thyroid cancer	8.76e-05	0.000922	CbGpPWpGaD
Mefenamic acid—Dizziness—Doxorubicin—thyroid cancer	8.67e-05	0.000652	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.56e-05	0.000901	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	8.43e-05	0.000886	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CALCA—thyroid cancer	8.42e-05	0.000886	CbGpPWpGaD
Mefenamic acid—Nausea—Epirubicin—thyroid cancer	8.42e-05	0.000633	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	8.4e-05	0.000884	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CHST14—thyroid cancer	8.39e-05	0.000883	CbGpPWpGaD
Mefenamic acid—Vomiting—Doxorubicin—thyroid cancer	8.33e-05	0.000627	CcSEcCtD
Mefenamic acid—Rash—Doxorubicin—thyroid cancer	8.27e-05	0.000622	CcSEcCtD
Mefenamic acid—Dermatitis—Doxorubicin—thyroid cancer	8.26e-05	0.000622	CcSEcCtD
Mefenamic acid—Headache—Doxorubicin—thyroid cancer	8.21e-05	0.000618	CcSEcCtD
Mefenamic acid—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	8.21e-05	0.000863	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—TERT—thyroid cancer	8.16e-05	0.000859	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TRIM33—thyroid cancer	7.96e-05	0.000837	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CDK1—thyroid cancer	7.93e-05	0.000834	CbGpPWpGaD
Mefenamic acid—CYP2C9—Biological oxidations—RXRA—thyroid cancer	7.93e-05	0.000834	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TSHR—thyroid cancer	7.88e-05	0.000829	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—HIF1A—thyroid cancer	7.81e-05	0.000821	CbGpPWpGaD
Mefenamic acid—Nausea—Doxorubicin—thyroid cancer	7.79e-05	0.000586	CcSEcCtD
Mefenamic acid—AKR1C3—Signaling Pathways—PRKAR1A—thyroid cancer	7.75e-05	0.000815	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CDK1—thyroid cancer	7.62e-05	0.000802	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PPARG—thyroid cancer	7.57e-05	0.000797	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NDUFA13—thyroid cancer	7.48e-05	0.000787	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MEN1—thyroid cancer	7.4e-05	0.000779	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	7.26e-05	0.000764	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—MINPP1—thyroid cancer	7.16e-05	0.000753	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—HPGD—thyroid cancer	7.14e-05	0.000751	CbGpPWpGaD
Mefenamic acid—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	7.06e-05	0.000743	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—SLC5A5—thyroid cancer	7.05e-05	0.000742	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CHST14—thyroid cancer	7.03e-05	0.00074	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PTCH1—thyroid cancer	6.7e-05	0.000704	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	6.61e-05	0.000695	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—BRAF—thyroid cancer	6.46e-05	0.00068	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—NRG1—thyroid cancer	6.37e-05	0.00067	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SST—thyroid cancer	6.12e-05	0.000644	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—NRG1—thyroid cancer	6.12e-05	0.000644	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NDUFA13—thyroid cancer	6.08e-05	0.00064	CbGpPWpGaD
Mefenamic acid—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	6e-05	0.000632	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PTGS2—thyroid cancer	5.96e-05	0.000627	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—RXRA—thyroid cancer	5.92e-05	0.000623	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CALCA—thyroid cancer	5.9e-05	0.00062	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—MINPP1—thyroid cancer	5.82e-05	0.000613	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.79e-05	0.000609	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.76e-05	0.000606	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CHST14—thyroid cancer	5.72e-05	0.000602	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TERT—thyroid cancer	5.72e-05	0.000601	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—HPGD—thyroid cancer	5.67e-05	0.000596	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PPARG—thyroid cancer	5.56e-05	0.000585	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—TERT—thyroid cancer	5.49e-05	0.000578	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—HIF1A—thyroid cancer	5.47e-05	0.000575	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDK1—thyroid cancer	5.34e-05	0.000561	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TCF7L1—thyroid cancer	5.31e-05	0.000559	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—HIF1A—thyroid cancer	5.25e-05	0.000553	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—PTGS2—thyroid cancer	5.22e-05	0.000549	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PTEN—thyroid cancer	5.2e-05	0.000547	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NDUFA13—thyroid cancer	4.95e-05	0.000521	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.94e-05	0.00052	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	4.78e-05	0.000503	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.77e-05	0.000502	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CHST14—thyroid cancer	4.66e-05	0.00049	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—HPGD—thyroid cancer	4.61e-05	0.000485	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.6e-05	0.000484	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—PTEN—thyroid cancer	4.55e-05	0.000479	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—BRAF—thyroid cancer	4.53e-05	0.000476	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PTGS2—thyroid cancer	4.37e-05	0.00046	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—BRAF—thyroid cancer	4.35e-05	0.000458	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—NRG1—thyroid cancer	4.28e-05	0.000451	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—TPR—thyroid cancer	4.1e-05	0.000431	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—NRAS—thyroid cancer	4.06e-05	0.000427	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PRKAR1A—thyroid cancer	4.03e-05	0.000424	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TPR—thyroid cancer	3.89e-05	0.000409	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TERT—thyroid cancer	3.85e-05	0.000405	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PRKAR1A—thyroid cancer	3.82e-05	0.000402	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PTEN—thyroid cancer	3.81e-05	0.000401	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—HPGD—thyroid cancer	3.75e-05	0.000395	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PPARG—thyroid cancer	3.74e-05	0.000393	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.74e-05	0.000393	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—HIF1A—thyroid cancer	3.68e-05	0.000387	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.66e-05	0.000385	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.66e-05	0.000385	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MEN1—thyroid cancer	3.65e-05	0.000384	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PTGS2—thyroid cancer	3.51e-05	0.00037	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—KRAS—thyroid cancer	3.5e-05	0.000368	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CCND1—thyroid cancer	3.3e-05	0.000348	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—TPR—thyroid cancer	3.25e-05	0.000342	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.25e-05	0.000342	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PRKAR1A—thyroid cancer	3.2e-05	0.000337	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—PTEN—thyroid cancer	3.19e-05	0.000335	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—SLC5A5—thyroid cancer	3.07e-05	0.000323	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PTEN—thyroid cancer	3.06e-05	0.000322	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—BRAF—thyroid cancer	3.05e-05	0.00032	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.04e-05	0.00032	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—AKT1—thyroid cancer	2.99e-05	0.000315	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—HRAS—thyroid cancer	2.97e-05	0.000313	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PTGS2—thyroid cancer	2.94e-05	0.00031	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CALCA—thyroid cancer	2.91e-05	0.000306	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.9e-05	0.000305	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.88e-05	0.000303	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—NRAS—thyroid cancer	2.84e-05	0.000299	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.75e-05	0.000289	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—NRAS—thyroid cancer	2.73e-05	0.000288	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—TPR—thyroid cancer	2.65e-05	0.000279	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDK1—thyroid cancer	2.63e-05	0.000277	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—AKT1—thyroid cancer	2.62e-05	0.000276	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	2.61e-05	0.000274	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—RXRA—thyroid cancer	2.58e-05	0.000271	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PTEN—thyroid cancer	2.57e-05	0.00027	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.51e-05	0.000264	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—KRAS—thyroid cancer	2.45e-05	0.000258	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—SLC5A5—thyroid cancer	2.44e-05	0.000256	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.36e-05	0.000248	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—KRAS—thyroid cancer	2.35e-05	0.000248	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CCND1—thyroid cancer	2.22e-05	0.000234	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—AKT1—thyroid cancer	2.2e-05	0.000231	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TP53—thyroid cancer	2.18e-05	0.000229	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—TPR—thyroid cancer	2.16e-05	0.000227	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PTEN—thyroid cancer	2.15e-05	0.000226	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.12e-05	0.000223	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NRG1—thyroid cancer	2.11e-05	0.000222	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—HRAS—thyroid cancer	2.08e-05	0.000219	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—RXRA—thyroid cancer	2.05e-05	0.000215	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—HRAS—thyroid cancer	2e-05	0.00021	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.99e-05	0.000209	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.98e-05	0.000209	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.92e-05	0.000202	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—NRAS—thyroid cancer	1.91e-05	0.000201	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TERT—thyroid cancer	1.9e-05	0.0002	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.86e-05	0.000195	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—AKT1—thyroid cancer	1.84e-05	0.000193	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HIF1A—thyroid cancer	1.82e-05	0.000191	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—AKT1—thyroid cancer	1.77e-05	0.000186	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—RXRA—thyroid cancer	1.67e-05	0.000175	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—KRAS—thyroid cancer	1.65e-05	0.000173	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PPARG—thyroid cancer	1.63e-05	0.000171	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.62e-05	0.00017	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.61e-05	0.00017	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.51e-05	0.000159	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—BRAF—thyroid cancer	1.5e-05	0.000158	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—AKT1—thyroid cancer	1.48e-05	0.000156	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TP53—thyroid cancer	1.46e-05	0.000154	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—HRAS—thyroid cancer	1.4e-05	0.000147	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—RXRA—thyroid cancer	1.36e-05	0.000143	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.32e-05	0.000139	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PPARG—thyroid cancer	1.29e-05	0.000136	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTGS2—thyroid cancer	1.28e-05	0.000135	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—AKT1—thyroid cancer	1.24e-05	0.00013	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTEN—thyroid cancer	1.12e-05	0.000117	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PTEN—thyroid cancer	1.06e-05	0.000111	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PPARG—thyroid cancer	1.05e-05	0.000111	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NRAS—thyroid cancer	9.45e-06	9.94e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PTEN—thyroid cancer	8.87e-06	9.33e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PPARG—thyroid cancer	8.56e-06	9e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTGS2—thyroid cancer	8.27e-06	8.7e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KRAS—thyroid cancer	8.13e-06	8.55e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTEN—thyroid cancer	7.21e-06	7.59e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HRAS—thyroid cancer	6.91e-06	7.27e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTGS2—thyroid cancer	6.73e-06	7.08e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—AKT1—thyroid cancer	6.44e-06	6.77e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—AKT1—thyroid cancer	6.1e-06	6.42e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTEN—thyroid cancer	5.87e-06	6.18e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—AKT1—thyroid cancer	5.11e-06	5.38e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKT1—thyroid cancer	4.16e-06	4.37e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKT1—thyroid cancer	3.38e-06	3.56e-05	CbGpPWpGaD
